Four-year complete remission with reduced-dose PARP inhibitor in advanced-stage epithelial ovarian cancer harboring a BRCA1 mutation: a case report of a chemotherapy-intolerant patient with idiopathic thrombocytopenic purpura. [PDF]
Lu P +5 more
europepmc +1 more source
Pathophysiology of thrombotic thrombocytopenic purpura.
J. E. Sadler
semanticscholar +1 more source
Regarding "Challenges in diagnosing thrombotic thrombocytopenic purpura". [PDF]
Martins de Oliveira Filho C, Carney BJ.
europepmc +1 more source
Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics
M. Saha, Jenny K. McDaniel, X. Zheng
semanticscholar +1 more source
Predicting Outcomes and Optimizing Therapy in Thrombotic Thrombocytopenic Purpura: Insights on Caplacizumab Use from a Romanian Hematology Center. [PDF]
Preda DO +7 more
europepmc +1 more source
Bilious Pleural Effusion Following Cholecystostomy in an Immunocompromised Elderly Male. [PDF]
Al Radaideh A +6 more
europepmc +1 more source
Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
J. A. Hovinga +4 more
semanticscholar +1 more source
Multicentric Castleman disease (MCD) presenting with retiform purpura: A rare dermatologic manifestation of a systemic disease. [PDF]
Kassim S +5 more
europepmc +1 more source
Monitoring ADAMTS-13 conformation in immune-mediated thrombotic thrombocytopenic purpura: toward personalized management. [PDF]
Joly BS +5 more
europepmc +1 more source
Depression and cognitive deficits as long‐term consequences of thrombotic thrombocytopenic purpura
T. Falter +10 more
semanticscholar +1 more source

